Trial Bank
4,419 trials match
- SPRING: Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis
MSRelapsing MSPhase 4Running, not recruiting
fingolimod · Novartis Pharmaceuticals · 2020 · 14 participants
- NMOSD: Impact of a Structured Wellness Behavioral Intervention on Quality of Life in NMOSD
NMOSDNot a drug-phase studyRecruiting
Icahn School of Medicine at Mount Sinai · 2025 · 20 participants
- MS-FLOWER: MSCopilot Users' Feedback in Real Life - Outcomes Regarding Integration in Patients' pathWay and Users' ExpeRience
MSMS (type not specified)Not a drug-phase studyCompleted
Ad scientiam · 2025 · 62 participants
- HOBSCOTCH-MS-Efficacy Trial
MSProgressive MSNot a drug-phase studyRecruiting
Dartmouth-Hitchcock Medical Center · 2025 · 125 participants
- Understanding and Enhancing Human Health and Movement
MSMS (type not specified)Not a drug-phase studyRecruiting
Louis Stokes VA Medical Center · 2021 · 75 participants
- Aerobic Fitness in Multiple Sclerosis: The Relationship Between Balance and Sensory Dual-Tasking
MSRelapsing and progressiveRecruiting
Suleyman Demirel University · 2026 · 70 participants
- LTS18002: A study to investigate long-term safety and tolerability of frexalimab in participants with multiple sclerosis
MSRelapsing MSPhase 3Not yet recruiting
frexalimab · Sanofi-Aventis Recherche & Developpement · 2027 · 37 participants
- TG1101-RMS303: An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
MSRelapsing MSPhase 3Running, not recruiting
ublituximab · TG Therapeutics, Inc. · 2019 · 1,100 participants
- ADAs to Alemtuzumab
MSRelapsing MSCompleted
alemtuzumab · Queen Mary University of London · 2022 · 15 participants
- Oral Cladribine B-cell Study
MSMS (type not specified)Completed
Queen Mary University of London · 2019 · 10 participants
- ENABLE: A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
MSRelapsing MSRecruiting
TG Therapeutics, Inc. · 2024 · 2,000 participants
- OSSIA: A Study of Ocrelizumab Administered Subcutaneously in Participants With Multiple Sclerosis Who Switch From an Approved Anti-CD20 Therapy
MSRelapsing and progressivePhase 4Recruiting
Genentech, Inc. · 2026 · 100 participants
- SOLI: Switch to Ofatumumab and Level of Immunoglobulins
MSRelapsing MSRecruiting
ofatumumab · University Hospital, Lille · 2026 · 115 participants
- SONATA-MS: Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis
MSRelapsing MSRecruiting
ocrelizumab · Hoffmann-La Roche · 2026 · 1,800 participants
- A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
MSProgressive MSPhase 2Recruiting
Sundance Biosciences, Inc. · 2026 · 20 participants
- Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Susceptibility
MSMS (type not specified)Completed
National Institute of Neurological Disorders and Stroke (NINDS) · 2012 · 181 participants
- Natural History Study of Progressive Multifocal Leukoencephalopathy (PML)
MSMS (type not specified)Recruiting
National Institute of Neurological Disorders and Stroke (NINDS) · 2012 · 700 participants
- Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy
NMOSDRecruiting
inebilizumab · Amgen · 2027 · 60 participants
- A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
MSMS (type not specified)Recruiting
TG Therapeutics, Inc. · 2024 · 728 participants
- TG1101-RMS-PED304: Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
MSRelapsing MSPhase 2Phase 3Recruiting
fingolimod, ublituximab · TG Therapeutics, Inc. · 2026 · 240 participants
- TG1101-RMS-SC201: A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)
MSNMOSDRelapsing MSPhase 2Recruiting
ublituximab · TG Therapeutics, Inc. · 2026 · 350 participants
- Dry Needling in Multiple Sclerosis
MSMS (type not specified)Not a drug-phase studyRecruiting
University of South Florida · 2026 · 24 participants
- sSIT-MS: Short Sprint Interval Training in People With Multiple Sclerosis
MSMS (type not specified)Not a drug-phase studyCompleted
Universidad de León · 2026 · 40 participants
- A phase 2 trial assessing Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis – MODIF-MS
MSMS (type not specified)Phase 1Phase 2Suspended
Assistance Publique Hopitaux De Paris · 2024 · 80 participants
- OLERO: A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
MSRelapsing and progressivePhase 3Running, not recruiting
ocrelizumab · Hoffmann-La Roche · 2022 · 1,300 participants
- KRONOS: Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years
MSRelapsing MSRunning, not recruiting
Novartis Pharmaceuticals · 2023 · 106 participants
- PET-AON: Efgartigimod for the Treatment of Acute Optic Neuritis
Optic neuritisPhase 2Recruiting
efgartigimod alfa · Anastasia Vishnevetsky, MD, MPH · 2025 · 20 participants
- MS-PEKOS: Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation
MSMS (type not specified)Completed
Novartis Pharmaceuticals · 2024 · 134 participants
- OleroMAX: An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
MSMS (type not specified)Phase 3Recruiting
ocrelizumab · Hoffmann-La Roche · 2024 · 500 participants
- NeuroDIP: Neurogenetics and Multi-omics of Neuroinflammatory Diseases in Multiplex Families to Improve Patients Health
MOGADMSNMOSDNot a drug-phase studyNot yet recruiting
Institut National de la Santé Et de la Recherche Médicale, France · 2026 · 500 participants
- Biobank For MS And Other Demyelinating Diseases
ADEMMSNMOSDOptic neuritisTransverse myelitisEarly (CIS/RIS)Running, not recruiting
Accelerated Cure Project for Multiple Sclerosis · 2006 · 3,226 participants
- iCMS: iConquerMS™ - A Patient-Powered Research Network for Multiple Sclerosis
MSMS (type not specified)Recruiting
Accelerated Cure Project for Multiple Sclerosis · 2014 · 20,000 participants
- cosMOG: A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)
MOGADPhase 3Running, not recruiting
rozanolixizumab · UCB Biopharma SRL · 2022 · 113 participants
- FEMINISEP: Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis (MS), Compared to a Control Group
MSMS (type not specified)Not a drug-phase studyRecruiting
University Hospital, Bordeaux · 2023 · 160 participants
- PROVIDE: A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
MSRelapsing and progressiveRunning, not recruiting
TG Therapeutics, Inc. · 2024 · 16 participants
- A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
MSNMOSDRelapsing and progressivePhase 1Recruiting
azercabtagene zapreleucel · TG Therapeutics, Inc. · 2025 · 100 participants
- MSS: A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity
MSMS (type not specified)Phase 2Recruiting
Celgene · 2025 · 200 participants
- Effect of a Mobile Health App on Pain and Quality of Life in Patients With Neuropathic Pain in Multiple Sclerosis
MSMS (type not specified)Not a drug-phase studyCompleted
Meryem Kocaslan Toran · 2025 · 56 participants
- ZB020-03-001: A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
MSProgressive MSPhase 3Recruiting
orelabrutinib · Zenas BioPharma (USA), LLC · 2026 · 705 participants
- ZB020-03-002: A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
MSRelapsing and progressivePhase 3Recruiting
orelabrutinib · Zenas BioPharma (USA), LLC · 2026 · 990 participants
- Tai Chi Training for Persons With Multiple Sclerosis.
MSRelapsing MSNot a drug-phase studyRunning, not recruiting
Karolinska Institutet · 2025 · 35 participants
- EXO-MS: Evaluating the Effects of the EXOPULSE Suit on Mobility, Walking Ability, and Balance in People With Multiple Sclerosis
MSMS (type not specified)Not a drug-phase studyNot yet recruiting
Otto Bock Healthcare Products GmbH · 2026 · 100 participants
- ORION: A Study to Describe Multiple Sclerosis Patients Treated With Tolebrutinib as Per Label in a Real-world Setting
MSMS (type not specified)Recruiting
tolebrutinib · Sanofi · 2026 · 3,000 participants
- Evaluation of the Effect of Mental Imagery Training Combined With Modified Constraint-Induced Movement Therapy in Individuals With Multiple Sclerosis
MSMS (type not specified)Not a drug-phase studyNot yet recruiting
Hacettepe University · 2026 · 14 participants
- REAL-MS: REAL-MS: Observational Database Study of AHSCT and MS Therapies
MSRelapsing and progressiveRecruiting
Imperial College London · 2026 · 2,000 participants
- Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)
MSMS (type not specified)Recruiting
National Institute of Neurological Disorders and Stroke (NINDS) · 1992 · 3,750 participants
- T4MS: Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis
MSEarly (CIS/RIS)Not a drug-phase studyRecruiting
University Hospital, Bordeaux · 2021 · 150 participants
- A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)
MSMS (type not specified)Running, not recruiting
dimethyl fumarate, diroximel fumarate · Biogen · 2024 · 10,500 participants
- CLOU064C12306: Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
MSRelapsing MSPhase 3Recruiting
remibrutinib · Novartis Pharmaceuticals · 2025 · 400 participants
- Care in Multiple Sclerosis (MS)
MSRelapsing MSRecruiting
NYU Langone Health · 2025 · 300 participants
About this data
Where the data comes from
ClinicalTrials.gov, the EU Clinical Trials Register, ISRCTN, ChEMBL and Europe PMC, combined into the MSFrontier trial bank.
How it is collected
Registry records are collected automatically, duplicate records across registries are merged, and treatments, phases and populations are tagged by software from the registry data. When an error is reported, we fix the rule so the fix applies to every trial, and log it in the Corrections log.
Last update
Trial bank updated recently. Sources and corrections
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error